LPTX already made breakout at the strongest resistance (3.02-3.16). Then, it also found to rebound back at the same level (resistance become support). From this point of view, the entry can be made at the range. The profit level found at 4.10 for 1st TP and 4.96 for 2nd TP. Drop you comment for further information about LPTX and have a nice day.
Bullish flag, not confirmed yet. Could confirm this coming week. If confirmed: Price target = 5.50$ Stay humble, have fun, make money!
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer....
Broke out of ascending triangle Currently back-testing the break-out 4hr hidden bullish divergence on the MACD and RSI Stop = below diagonal support Target = Resistance
Potential long setup for your watchlist
I am looking at a break of the $2.60 level to confirm breakout. -Price tightening within wedge for 3+ months (depending on how you draw the wedge) and completing what appears to be the right shoulder of an IH&S. (The midline, as I have drawn it, fits very neatly). -Price has recently experienced bullish diverging of EMAs with recent strong support found at the 50...
FDA approval date on 03.28.2020
Leap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly. As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent. The technical's are now aligning with some key dates with a potential short...
Possible retracement to 200-Day MA ($3.00). Series of higher lows on the 2-month chart!
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a...
*****SPECULATION IS WE COULD GET A SIZEABLE MOVE IN THE STOCK TODAY WITH W EASY 30% GAIN********************* SET ALERTS FOR A POSSIBLE MOVE TO ABOVE $2 AVERAGE PRICE TARGET $9 AVERAGE RECOMMENDATION buy LEAP THERAPEUTICS INC. Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat...
LPTX has formed an inverse head and shoulders. Stocks like this are challenging to assess. They just do not have the technical history required. Never the less, i think this could be a solid play. Massive inverse H&S with ok indicator conformation.